open access

Vol 13, No 4 (2017)
Case report
Published online: 2017-09-13
Get Citation

Efficacy of regorafenib in gastrointestinal stromal tumors (GISTs) – a case report.

Iwona Ługowska, Anna Dawidowska, Anna Klimczak, Piotr Rutkowski
DOI: 10.5603/OCP.2017.0022
·
Oncol Clin Pract 2017;13(4):177-180.

open access

Vol 13, No 4 (2017)
CASE REPORTS
Published online: 2017-09-13

Abstract

The systemic treatment of gastrointestinal stromal tumors is based on targeted therapies such as imatinib, sunitinib, sorafenib or regorafenib. The important treatment option is recruitment onto clinical trials specially in late stage of disease.

The presented case concerns the 62 year-old woman with metastatic GIST. In 2008 after gastrectomy she was recruited to EORTC 62024 clinical trial. Here she was randomly assigned to the observational arm. In 2009 due to non-resectable recurrence, the imatinib therapy was started and continued until 2014. At this time, she experienced disease progression so imatinib dose was doubled, and due to further progression – she received sunitinib. The tolerance of imatinib was satisfactory, but after sunitinib therapy - the dose modification was necessary due to toxicity at grade CTC3. In 2015, because of the further progression she received sorafenib over 12 months, and next re-treatment with imatinib and chemotherapy according to the ADIC with 4 months of response. Considering patient’s good performance status regardless the fifth line of treatment she was proposed the regorafenib treatment. After the first course, patient reported a definite improvement of quality of life and pain control. The main complications was the hand-foot syndrome and diarrheas (grade CTC2). The best response was partial response, nowadays patient disease is stable. In the case of further progression a clinical trial will be proposed.

Conclusions: In GIST patients, regorefenib as an single agent administered after progression on imatinib, sunitinib and sorafenib is effective and well tolerated treatment leading into clinical and radiological response.

Abstract

The systemic treatment of gastrointestinal stromal tumors is based on targeted therapies such as imatinib, sunitinib, sorafenib or regorafenib. The important treatment option is recruitment onto clinical trials specially in late stage of disease.

The presented case concerns the 62 year-old woman with metastatic GIST. In 2008 after gastrectomy she was recruited to EORTC 62024 clinical trial. Here she was randomly assigned to the observational arm. In 2009 due to non-resectable recurrence, the imatinib therapy was started and continued until 2014. At this time, she experienced disease progression so imatinib dose was doubled, and due to further progression – she received sunitinib. The tolerance of imatinib was satisfactory, but after sunitinib therapy - the dose modification was necessary due to toxicity at grade CTC3. In 2015, because of the further progression she received sorafenib over 12 months, and next re-treatment with imatinib and chemotherapy according to the ADIC with 4 months of response. Considering patient’s good performance status regardless the fifth line of treatment she was proposed the regorafenib treatment. After the first course, patient reported a definite improvement of quality of life and pain control. The main complications was the hand-foot syndrome and diarrheas (grade CTC2). The best response was partial response, nowadays patient disease is stable. In the case of further progression a clinical trial will be proposed.

Conclusions: In GIST patients, regorefenib as an single agent administered after progression on imatinib, sunitinib and sorafenib is effective and well tolerated treatment leading into clinical and radiological response.

Get Citation

Keywords

GIST, regorafenib, metastatic, management

About this article
Title

Efficacy of regorafenib in gastrointestinal stromal tumors (GISTs) – a case report.

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 4 (2017)

Article type

Case report

Pages

177-180

Published online

2017-09-13

DOI

10.5603/OCP.2017.0022

Bibliographic record

Oncol Clin Pract 2017;13(4):177-180.

Keywords

GIST
regorafenib
metastatic
management

Authors

Iwona Ługowska
Anna Dawidowska
Anna Klimczak
Piotr Rutkowski

References (29)
  1. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv. 2001; 438(1): 1–12.
  2. Kindblom L.G. Remotti H.E. Aldenborg F. Meis-Kinblom .M.: Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristic of the interstitial cell of Cajal. Am J Pathol. 1998; 152: 1259–1269.
  3. Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002; 33(5): 459–465.
  4. Huss S, Pasternack H, Ihle MA, et al. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. Hum Pathol. 2017; 62: 206–214.
  5. Debiec-Rychter M, Dumez H, Judson I, et al. EORTC Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004; 40(5): 689–695.
  6. Szucs Z, Thway K, Fisher C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017; 13(1): 93–107.
  7. Wozniak A, Floris G, Debiec-Rychter M, et al. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies. Cancer Invest. 2010; 28(8): 839–848.
  8. Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor. Curr Opin Oncol. 2006; 18(4): 386–395.
  9. http://www.esmo.org/Guidelines/Sarcoma-and-GIST/Gastrointestinal-Stromal-Tumours.
  10. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008; 26(4): 626–632.
  11. Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007; 14(7): 2018–2027.
  12. Demetri G, Mehren Mv, Blanke C, et al. Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine. 2002; 347(7): 472–480.
  13. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23): 4342–4349.
  14. Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, et al. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS). Annals of Surgical Oncology. 2015; 22(9): 2948–2957.
  15. Blanke C, Demetri G, Mehren Mv, et al. Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. Journal of Clinical Oncology. 2008; 26(4): 620–625.
  16. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364(9440): 1127–1134.
  17. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006; 24(29): 4764–4774.
  18. Zalcberg JR, Verweij J, Casali PG, et al. EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005; 41(12): 1751–1757.
  19. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005; 23(24): 5795–5804.
  20. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544): 1329–1338.
  21. Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015; 121(9): 1405–1413.
  22. Rutkowski P, Bylina E, Klimczak A, et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer. 2012; 12: 107.
  23. Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015; 121(9): 1405–1413.
  24. Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer. 2013; 49(5): 1027–1031.
  25. Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs. 2012; 30(6): 2377–2383.
  26. Demetri GD, Reichardt P, Kang YK, et al. GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 295–302.
  27. Chan SL, Ma BBy. An update on the safety and efficacy of regorafenib in the treatment of solid cancers. Expert Opin Drug Metab Toxicol. 2014; 10(11): 1607–1614.
  28. Overton LC, Heinrich MC. Regorafenib for treatment of advanced gastrointestinal stromal tumors. Expert Opin Pharmacother. 2014; 15(4): 549–558.
  29. https://clinicaltrials.gov/ct2/results?cond=Gastrointestinal+Stromal+Tumors&term=&cntry1=&state1=&recrs=a.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl